Fecal transplant is a standard procedure these days, and it is acclaimed for its innovative approach. Unfortunately, apart from being so successful, this transplant leads to the death of a person and another critically sick last spring. The doctors who were involved in the operation have come forward to explain what exactly happened. An article was published in the New England Journal of Medicine, where many medical professionals from Massachusetts General Hospital give detail about their mistake in the deadly fecal transplant. They also hope that further, they will able to eliminate such risks about this new technology. Dr. Elizabeth L.Hohmann, who is the primary author of this article, said, “it was something very challenging for the professionals.” “But it is a preventive incident related to the risk of latest projects.”
Several clinical trials are taking place for the procedure of FMT that relocate feces from a donor who is healthy enough into a sick person’s intestinal tract. This is a method to reinstate healthy bacteria to the bowel. According to the report of the Times, this procedure is not approved by the Food and Drug administration yet. However, this treatment has successfully treated a dangerous bacterial infection, Clostridium difficile. A 73-year-old man who died last year had cancer. He and other patients who fell sick was given treatment from the same stool in two differentiated FMT experimental trials, including leukemia and liver disorder, each.
The Times reported the stool which was used to treat both of the patients was contaminated with a string of bacteria called E. coli. The doctors gave this statement. Hohmann further said that none of the doctors thought of testing the material before using it on the patients. Once the contaminated stool gets transferred to both the patients, they became ill. The liver patient was given some powerful antibiotics due to which he was able to recover, but the cancer patient died after 10 days of his transplant. The agency has a plan for a public hearing next week in Washington, D.C., to discuss the benefits and risks associated with this procedure.